New hope for teens with stubborn hives: xolair shows promise

NCT ID NCT06053801

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether Xolair (omalizumab) is safe and works for Chinese teenagers with chronic spontaneous urticaria (long-term hives and itching) that doesn't get better with standard antihistamines. 55 teens took part, receiving Xolair for 12 weeks, followed by 4 weeks of safety check-ups. The main goal was to track side effects and see how well the drug reduced itching.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Novartis Investigative Site

Fuzhou, Fujian, 350025, China
Novartis Investigative Site

Guangzhou, Guangdong, 510091, China
Novartis Investigative Site

Changsha, Hunan, 410008, China
Novartis Investigative Site

Nantong, Jiangsu, 226000, China
Novartis Investigative Site

Dalian, Liaoning, 116000, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310001, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site

Beijing, 100069, China
Novartis Investigative Site

Shanghai, 200443, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.